4.0 Article

Hematologically important mutations: X-linked chronic granulomatous disease (fourth update)

Journal

BLOOD CELLS MOLECULES AND DISEASES
Volume 90, Issue -, Pages -

Publisher

ACADEMIC PRESS INC ELSEVIER SCIENCE
DOI: 10.1016/j.bcmd.2021.102587

Keywords

gp91(phox); Chronic granulomatous disease; Mutation; CYBB; G6PD; NADPH oxidase; X-linked disease

Categories

Funding

  1. Di-vision of Intramural Research, National Institute of Allergy and Infec-tious Diseases, National Institutes of Health
  2. National Cancer Institute, National Institutes of Health [HHSN261200800001E]
  3. University Grenoble Alpes (UGA)
  4. Interreg France-Suisse [Programme de Cooperation Territoriale Europeenne, Fond Europeen de Developpement Regional (FEDER) , 2017-2019]
  5. Delegation for Clinical Research and Innovations, University Hospital Grenoble Alpes (CHUGA) (DRCI, Rementips project 2014)
  6. KU Leuven [C16/18/007]
  7. VIB GC PID Grant
  8. CSL Behring Chair of Primary Immunodeficiencies [G0C8517N]
  9. Jeffrey Modell Foundation

Ask authors/readers for more resources

Chronic Granulomatous Disease (CGD) is a rare immunodeficiency disorder characterized by a lack of superoxide production due to NADPH oxidase deficiency, leading to ineffective microbial killing. Majority of patients have mutations in the CYBB gene, while variations in the G6PD gene may also result in similar symptoms.
Chronic granulomatous disease (CGD) is an immunodeficiency disorder affecting about 1 in 250,000 individuals. CGD patients suffer from severe bacterial and fungal infections. The disease is caused by a lack of superoxide production by the leukocyte enzyme NADPH oxidase. Superoxide and subsequently formed other reactive oxygen species (ROS) are instrumental in killing phagocytosed micro-organisms in neutrophils, eosinophils, monocytes and macrophages. The leukocyte NADPH oxidase is composed of five subunits, of which the enzymatic component is gp91(phox), also called Nox2. This protein is encoded by the CYBB gene on the X chromosome. Mutations in this gene are found in about 70% of all CGD patients in Europe and in about 20% in countries with a high ratio of parental consanguinity. This article lists all mutations identified in CYBB and should therefore help in genetic counseling of X-CGD patients' families. Moreover, apparently benign polymorphisms in CYBB are also given, which should facilitate the recognition of disease-causing mutations. In addition, we also include some mutations in G6PD, the gene on the X chromosome that encodes glucose-6-phosphate dehydrogenase, because inactivity of this enzyme may lead to shortage of NADPH and thus to insufficient activity of NADPH oxidase. Severe G6PD deficiency can induce CGD-like symptoms.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.0
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available